<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND:: Bevacizumab plus doublet chemotherapy has become one of the standard treatments for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>We have investigated the efficacy and safety of bevacizumab plus <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> as first-line chemotherapy for Korean patients with mCRC </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS:: Patients were treated with bevacizumab 7.5 mg/kg and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> 130 mg/m on day 1 and <z:chebi fb="0" ids="31348">capecitabine</z:chebi> 2000 mg/m/d on days 1 to 14 </plain></SENT>
<SENT sid="3" pm="."><plain>After 9 cycles, patients were entered into the maintenance treatment, consisting of bevacizumab and <z:chebi fb="0" ids="31348">capecitabine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment was repeated every 3 weeks and response was evaluated every 2 cycles </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS:: Of the 49 patients (median age, 57 y), 29 (59%) had <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> in the colon, and 31 (63%) had <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in 2 or more organs </plain></SENT>
<SENT sid="6" pm="."><plain>Overall response rate was 71.4% [95% confidence interval (CI), 58.7%-84.1%], median progression-free survival was 10.4 months (95% CI, 8.2-12.5 mo), and median overall survival was 20.0 months (95% CI, 16.7-23.4 mo) </plain></SENT>
<SENT sid="7" pm="."><plain>Frequent grade 3 toxicities included <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (9, 18.4%), <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (8, 16.3%), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (6, 12.2%), and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (3, 6.1%) </plain></SENT>
<SENT sid="8" pm="."><plain>Bevacizumab-related grade 3 or 4 toxicities included <z:hpo ids='HP_0000093'>proteinuria</z:hpo> (1, 2.0%) and bowel <z:mpath ids='MPATH_81'>perforation</z:mpath> (1, 2.0%) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS:: Bevacizumab plus <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> was well tolerated and showed promising antitumor activity in Korean patients with mCRC </plain></SENT>
</text></document>